ARDX (Ardelyx) Interest Expense : $-20.1 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ardelyx's interest expense for the three months ended in Dec. 2024 was $ -5.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-20.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ardelyx's Operating Income for the three months ended in Dec. 2024 was $ 8.1 Mil. Ardelyx's Interest Expense for the three months ended in Dec. 2024 was $ -5.9 Mil. Ardelyx's Interest Coverage for the quarter that ended in Dec. 2024 was 1.39. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ardelyx Interest Expense Historical Data

The historical data trend for Ardelyx's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Interest Expense Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-5.10

-4.50

-5.07

-8.87

-20.09

Ardelyx Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-2.81	-4.06	-4.90	-5.28	-5.85

Ardelyx Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.1 Mil.

Ardelyx (NAS:ARDX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ardelyx's Interest Expense for the three months ended in Dec. 2024 was $-5.9 Mil. Its Operating Income for the three months ended in Dec. 2024 was $8.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $151.9 Mil.

Ardelyx's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	8.125	/	-5.853
	=	1.39

The higher the ratio, the stronger the company's financial strength is.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

41X:Germany 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Executives

Michael Raab	director, officer: President & CEO	1119 ST PAUL STREET, BALTIMORE MD 21202
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Laura A Williams	officer: Chief Medical Officer	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Justin A Renz	officer: Chief Financial Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer	officer: See Remarks	78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks	officer: See Remarks	C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
David P. Rosenbaum	officer: Chief Development Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Robert Ora Felsch	officer: See Remarks	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Susan Rodriguez	officer: Chief Commercial Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Jeffrey W Jacobs	officer: VP, Chemistry	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli	officer: See Remarks	C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010